Therapies targeting CAFs have proved effective in overcoming treatment resistance in HER2+ breast cancer, with increased expression of NK-IL2RS, NK, and NKT cell signatures before treatment correlating with improved response to anti-HER2 mAbs-based therapy (310). The gene discussed is ERBB2; the disease is breast carcinoma.